Journal: Cancer gene therapy

Article Title: BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma.

doi: 10.1038/s41417-024-00805-4

Figure Lengend Snippet: Fig. 3 A representative western blot of the siRNA transfection experiment. A The blot of siRNA BAG2 and MDK, C the blot of siRNA MAD2L1. β-Tubulin was used as a loading control and GAPDH was the positive control of the siRNA transfection. As shown in the blots and also in graphs (B) and (D) there was a significant reduction of the protein level in the silenced cells, as compared to the negative CTRL. E Graph showing the comparison of protein expression in MeT-5A and MSTO cell lines of BAG2, MAD2L1, and MDK (Mann–Whitney test; p value < 0.05 were considered significant, p value = 0.0332(*), 0.0021(**), 0.0002(***), <0.0001(****)).

Article Snippet: IHC was carried out on 3.5 μm paraffin sections by using recombinant AntiBAG2 Rabbit mAb [EPR3567] (1:400), Anti-Midkine Rabbit mAb [EP1143Y] (1:100; cod ab79406, ab52637; Abcam, Cambridge, MA, USA), and AntiMAD2 (MAD2L1) Rabbit pAb (1:250; cod TA308923; OriGene, Rockville, MD, USA).

Techniques: Western Blot, Transfection, Control, Positive Control, Comparison, Expressing, MANN-WHITNEY

Journal: Cancer gene therapy

Article Title: BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma.

doi: 10.1038/s41417-024-00805-4

Figure Lengend Snippet: Fig. 4 Viability, proliferation and caspase assays after gene silencing. A AOC of MeT-5A and MSTO at 72 h after treatment with siRNA- negative-control (siRNA CTRL−), siRNA BAG2, siRNA MAD2L1, siRNA MDK. The AOC is normalized to the time of transfection (t0). B Overall, FI of MeT-5A and MSTO was measured at 72 h after silencing; the graphs show the comparison between MeT-5A and MSTO for the three-siRNA transfection. ANOVA test; p value = 0.0332(*), 0.0021(**), 0.0002(***), <0.0001(****). C–E End point of apoptosis analysis in MSTO and MeT-5A cells in the presence of 5 µM caspase 3/7 Green Dye and siRNA BAG2, siRNA MAD2L1, and siRNA MDK, respectively. Mann–Whitney test; p value 0.0332(*), 0.0021(**), 0.0002(***), <0.0001(****).

Article Snippet: IHC was carried out on 3.5 μm paraffin sections by using recombinant AntiBAG2 Rabbit mAb [EPR3567] (1:400), Anti-Midkine Rabbit mAb [EP1143Y] (1:100; cod ab79406, ab52637; Abcam, Cambridge, MA, USA), and AntiMAD2 (MAD2L1) Rabbit pAb (1:250; cod TA308923; OriGene, Rockville, MD, USA).

Techniques: Negative Control, Transfection, Comparison, MANN-WHITNEY

Journal: Cancer gene therapy

Article Title: BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma.

doi: 10.1038/s41417-024-00805-4

Figure Lengend Snippet: Fig. 7 Representative immunohistochemical staining of MPM samples showing intense expression of MDK, MAD2L1, and BAG2 proteins in tumor cells (brown staining). A–D Representative BAG2 immunostainings in RMP, EMM, BMM, and SMM, respectively. Moderate to strong expression in the three types of MPM, while no expression is visible in the hyperplastic mesothelium in RMP (red arrow). E–H Representative MAD2L1 immunostainings in RMP, EMM, BMM, and SMM, respectively. Strong expression is present in the three types of MPM, but there are areas of discernable expression in the mesothelial cells on the pleural surface in RMP as well (blue arrow positive mesothelial area, red arrow negative area). I–L Representative MDK immunostainings in RMP, EMM, BMM, and SMM, respectively. Strong expression is seen in the three types of MPM; however, some focal expression is also detectable in the mesothelial cells on the pleural surface in RMP (blue arrow focal staining, red arrow negative staining). Magnification: RMPs ×400, MPMs ×200.

Article Snippet: IHC was carried out on 3.5 μm paraffin sections by using recombinant AntiBAG2 Rabbit mAb [EPR3567] (1:400), Anti-Midkine Rabbit mAb [EP1143Y] (1:100; cod ab79406, ab52637; Abcam, Cambridge, MA, USA), and AntiMAD2 (MAD2L1) Rabbit pAb (1:250; cod TA308923; OriGene, Rockville, MD, USA).

Techniques: Immunohistochemical staining, Staining, Expressing, Negative Staining

Journal: Cancer gene therapy

Article Title: BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma.

doi: 10.1038/s41417-024-00805-4

Figure Lengend Snippet: Fig. 8 Quantification of protein expression in RMP vs MPM as assessed by IHC and H-score. Graphs for BAG2 immunostaining in RMP vs MPM regardless of subtype (A) and RMP vs the different subtypes of MPM (B), respectively. Graphs for MAD2L1 immunostaining in RMP vs MPM regardless of subtype (C) and RMP vs the different subtypes of MPM (D), respectively. Graphs for MDK immunostaining in RMP vs MPM regardless of subtype (E) and RMP vs the different subtypes of MPM (F), respectively. Kruskal–Wallis test followed by a post hoc Dunn’s test with Bonferroni correction was used to evaluate the statistical difference between the median of each group, p value <0.001(***), <0.01(**), <0.05(*).

Article Snippet: IHC was carried out on 3.5 μm paraffin sections by using recombinant AntiBAG2 Rabbit mAb [EPR3567] (1:400), Anti-Midkine Rabbit mAb [EP1143Y] (1:100; cod ab79406, ab52637; Abcam, Cambridge, MA, USA), and AntiMAD2 (MAD2L1) Rabbit pAb (1:250; cod TA308923; OriGene, Rockville, MD, USA).

Techniques: Expressing, Immunostaining